IXCHIQ

关于IXCHIQ

IXCHIQ is the world’s first and only licensed chikungunya vaccine available to address this significant unmet medical need. The vaccine is currently approved in the U.S.[1], Europe[2], and Canada[3] for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. The U.S. launch is underway while first sales in Canada and Europe are anticipated in the fourth quarter of 2024.

时间表

Single dose.

副作用

Well tolerated; occasional headache, myalgia, fatigue, and fever.

我们监测世界各地的旅行中断或威胁事件,并通知您,这样您就不会遇到任何意外情况。

了解更多